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Abstract
Background: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ
dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or
effective in this setting. Further, these patients are often not candidates for other anti-cancer therapies, highlighting
their need for active treatment options.
Methods: We performed a retrospective analysis of patients from multiple centers with advanced solid tumors and
baseline organ dysfunction who received anti-PD-1 therapy. Organ dysfunction was defined as cardiac (left
ventricular ejection fraction ≤45 %), renal (creatinine ≥2 mg/dL or GFR ≤30 ml/min) or hepatic dysfunction
(evidence of cirrhosis on imaging or AST, ALT or bilirubin ≥3x ULN). We assessed change in organ dysfunction,
immune related adverse events (irAEs), response rate, progression free survival (PFS) and overall survival (OS).
Results: We identified 27 patients eligible for inclusion with the following diseases: renal cell carcinoma (n = 8),
melanoma (10), non-small cell lung cancer (3), small cell lung cancer (2) and urothelial bladder cancer (4). Baseline
organ dysfunction included renal dysfunction (n = 17), hepatic dysfunction (7), cardiac dysfunction (11), including >1
organ dysfunction (8). Worsening organ dysfunction requiring hospitalization or dose delays occurred in 8 patients
(30 %) although in most cases this was thought not-drug related and resolved with supportive care. Grade 3 irAEs
occurred in 2 pts (7 %; hepatitis and colitis). Thirteen of 27 patients had ongoing treatment benefit (objective response
or stable disease) at data collection (48 %). Eleven patients had primary progressive disease (41 %), 11 had stable
disease (41 %), 4 had partial responses (15 %), and one had a complete response (4 %). Overall, median PFS was
168 days. Median OS was not reached.
Conclusions: In our experience, anti-PD-1 agents in this group of patients with cardiac, hepatic or renal dysfunction
were associated with tolerable irAEs and infrequent manageable worsening of organ dysfunction. Further, objective
responses and prolonged PFS were observed in a number of patients. Thus, patients with baseline organ dysfunction
may be considered for anti-PD-1 therapy with appropriate clinical monitoring.
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Background
Agents that block the interaction between programmed
death-1 receptor and its ligand (PD-1/PD-L1) inhibit this
negative immune regulator and thereby unleash anti-
tumor immune responses. These agents, including nivo-
lumab and pembrolizumab, have produced objective re-
sponses, many of which are durable, in numerous solid
and hematologic malignancies [1–8]. As these agents are
incorporated into standard treatment algorithms, ques-
tions have arisen regarding their use in patient popula-
tions excluded from clinical trials, including those with
organ dysfunction.
Advanced malignancies have traditionally been treated
with cytotoxic chemotherapy. Unfortunately, many pa-
tients have limited baseline organ function and/or per-
formance status and are unable to receive optimal
chemotherapy regimens. As such, they may have ex-
tremely limited therapeutic options. Due to their phar-
macokinetic and pharmacodynamic properties, cytotoxic
chemotherapies frequently result in bone marrow sup-
pression, kidney and liver dysfunction, and cardiac tox-
icity. In patients that are further limited by baseline
organ dysfunction, chemotherapy may exacerbate exist-
ing organ injury or result in decreased clearance or me-
tabolism, increasing toxicities. By contrast, monoclonal
antibodies are metabolized to peptides and amino acids
by circulating phagocytic cells or by their target antigen-
containing cells, rather than through the liver and kid-
neys [9]. Monoclonal antibodies bound to protective re-
ceptors are protected from degradation, explaining their
exceptionally long half-lives [10].
These pharmacologic and immune properties result in
a distinct toxicity profile specific to immunotherapies.
These idiosyncratic adverse events, termed immune re-
lated adverse events (irAEs), include colitis, pneumonitis,
hepatitis, nephritis, and endocrinopathies [11]. Although
usually manageable with corticosteroids, irAEs represent a
significant cause of morbidity and rarely mortality.
The effects of anti-PD-1 in patients with baseline organ
dysfunction have not been explored. We hypothesized
that, based on their pharmacokinetics and mechanism of
action, anti-PD-1 therapies would not induce worsening
organ dysfunction or high rates of irAEs in this popula-
tion. To address, we performed a retrospective analysis of
patients from four centers with pre-existing organ dys-
function treated with anti-PD-1 agents. We assessed safety
endpoints, including irAEs and worsening organ dysfunc-
tion, and efficacy endpoints.
Methods
Patients
Eligible patients were 18 years of age or older, had a con-
firmed advanced malignancy, and had received at least
one dose of either pembrolizumab or nivolumab between
6/1/2013 and 12/31/2015. Further inclusion criteria in-
cluded access to medical records and baseline organ
dysfunction. Organ dysfunction was defined as the fol-
lowing: 1) creatinine ≥2 mg/dL or estimated glomerular
filtration rate (eGFR) ≤ 30 mL/min; 2) aspartate amino-
transferase (AST), alanine aminotransferase (ALT), or
total bilirubin ≥ 3 times institution upper limit of nor-
mal, or evidence of cirrhosis on imaging studies; and 3)
ejection fraction ≤ 45 %. These particular organ systems
were chosen since they often preclude clinical trial en-
rollment when dysfunctional. Dysfunction of other or-
gans, including lungs, bone marrow, and brain were not
assessed due to less objective measurements, less rou-
tine monitoring, and multifactorial nature of dysfunc-
tion. The cutoffs for particular organ dysfunction were
somewhat arbitrary, but would often exclude patients
from many clinical trials and/or from various chemo-
therapy regimens. Key exclusion criteria included pa-
tients who received combination immunotherapy with
multiple agents (e.g. ipilimumab + nivolumab).
Study design
This was a multicenter, retrospective analysis of patients
with baseline organ dysfunction who received either pem-
brolizumab or nivolumab for the treatment of advanced
malignancies. We collected patient demographics, organ
function, medical co-morbidities, and Eastern Cooperative
Group performance status (ECOG PS) at baseline.
Outcomes
Safety endpoints were (1) new or progressive organ
dysfunction defined as baseline dysfunction above, (2)
hospitalization rate, and (3) adverse events as defined
in the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE version
4.03). Efficacy outcomes were (1) progression-free sur-
vival (PFS), (2) overall survival (OS), and (3) response
rate per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1.
Statistical analysis
Baseline demographics and treatment characteristics
were analyzed using descriptive statistics, listed with fre-
quencies and percentages for categorical variables and
medians and ranges for continuous variables. PFS was
defined as time from first dose of anti-PD-1 therapy to
progression of disease via scans or documentation of
progression in provider notes. OS was defined as the
time from first dose of therapy to death from any cause.
All surviving patients were censored at the time of last
follow up. Survival distributions were estimated using
the Kaplan-Meier method.
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Results
Patients
A total of 27 patients with advanced malignancies and
baseline organ dysfunction were included. Eight (30 %)
had renal cell carcinoma (RCC), 10 (37 %) had melan-
oma, 3 (11 %) had non-small cell lung cancer (NSCLC),
2 (7 %) had small cell lung cancer (SCLC), and 4 (15 %)
had urothelial bladder carcinoma. Most patients were
male with a median age of 69, and a majority received
nivolumab as their anti-PD-1 therapy. The median
ECOG PS was 1 with a range from 0–3. Baseline patient
characteristics are shown in Table 1. The majority of pa-
tients received ≥2 prior lines of treatment before anti-
PD-1 therapy (n = 20, 74 %). The prevalence of baseline
organ dysfunction was as follows: renal (N= 17, 63 %),
hepatic (N= 7, 26 %), and cardiac (N= 11, 41 %) dysfunc-
tion. Eight (30 %) patients had dysfunction in multiple
organ systems at baseline. All patients had comorbidities
in addition to cancer.
Among 17 patients with renal dysfunction, 3 were on
hemodialysis or peritoneal dialysis. Causes of renal dys-
function were diverse, but included diabetes, hyperten-
sion, prior therapies (tyrosine kinase inhibitors), and
nephrectomy (for RCC). Median creatinine was 2.7
(range 2–7.2 in the setting of hemodialysis). Among 7
patients with hepatic dysfunction, 4 had evidence of cir-
rhosis on imaging, including 2 with splenomegaly and
gastroesophageal varices. Cirrhosis was caused by alco-
hol ingestion (n = 3) and hepatitis C (n = 1). Two pa-
tients had elevated bilirubin (baseline of 2.1 and 4.0
respectively), and two patients had elevated liver func-
tion tests (AST 123–150), all caused by metastatic
disease. Among 11 patients with cardiac dysfunction,
ejection fraction ranged from 10 to 45 %. Causes of car-
diac dysfunction were primarily due to ischemia but also
included alcoholic cardiomyopathy (n = 1) and several
patients with hypertension and prior tyrosine kinase
inhibitors in addition to coronary artery disease.
Safety
Following anti-PD-1 therapy, irAEs were uncommon;
two patients (7 %) experienced grade 3 irAEs, account-
ing for three total events (Table 2). One patient had
metastatic RCC with baseline renal (creatinine 3.3) and
cardiac dysfunction (ejection fraction 25–30 %) experi-
enced grade 3 hepatitis that resolved with corticosteroids
(prednisone 1 mg/kg tapered over 1 month). The other
patient had NSCLC with a history of follicular lymph-
oma and renal dysfunction at baseline (baseline creatin-
ine 4.6), and experienced grade 3 hepatitis and colitis
which emerged concurrently and rapidly resolved with
high-dose (1 mg/kg) prednisone. This patient discontin-
ued therapy and was the only patient to do so due to
toxicities.
Next, we assessed the effects of anti-PD-1 treatment
on patients’ baseline organ dysfunction. We did not ob-
serve irAEs leading to obvious worsening of patient’s
organ function. Worsening organ function occurred in
eight patients (30 %, Table 3), all thought to be unrelated
to anti-PD-1 therapy. Three patients with baseline renal
dysfunction experienced low-grade acute kidney injury,
thought to be related to volume depletion (either due to
decreased oral intake or excess diuresis). These resolved
with hydration or adjustment of diuretic doses and did
not require corticosteroids (e.g. unrelated to anti-PD-1
therapy by provider assessment). Five patients (4 with
baseline congestive heart failure, 1 with cirrhosis) expe-
rienced volume overload, including four requiring
hospitalization for diuresis. All of these cases occurred
within the first 12 weeks of therapy. These did not recur
with adjustment of oral diuretic doses, with or without
Table 1 Baseline characteristics
Baseline features (n = 27) N (%)
Median age, years (range) 69 (47–85)
Male 23 (85)
≥2 prior therapies 20 (74)
Organ dysfunction
Renal dysfunction 17 (63)
Hepatic dysfunction 7 (26)
Cardiac dysfunction 11 (41)
2 organ dysfunctions 8 (30)
Received nivolumab 16 (59)
Median number of doses (range) 7 (1–52)
Disease state
Renal cell carcinoma 8 (30 %)
Melanoma 10 (37 %)
Non-small cell lung cancer 3 (11 %)
Small cell lung cancer 2 (7 %)
Urothelial cell carcinoma 4 (15 %)
Table 2 Immune-related adverse events
irAE Grades 1/2 (N, %) Grades 3/4 (N, %)
Arthralgias 1 (4 %) 0
Colitis 0 1 (4 %)
Conjunctivis 1 (4 %) 0
Diarrhea 1 (4 %) 0
Hepatitis 0 2 (7 %)
Hypothyroidism 4 (15 %) 0
Nephritis 2 (7 %) 0
Pruritis 1 (4 %) 0
Rash 3 (11 %) 0
Vitiligo 1 (4 %) 0
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concurrent use of intravenous diuretics during anti-PD-
1 infusion. One case of refractory ascites of unclear eti-
ology developed in a patient with metastatic RCC (but
without significant abdominal involvement) and baseline
kidney dysfunction (creatinine 2.2) requiring repeated
paracentesis that was considered unrelated to anti-PD-1
therapy. An immune-related etiology was briefly consid-
ered, but no improvement was noted with prednisone.
Notably, performance status appeared similar in patients
who experienced organ dysfunction exacerbations and
those who did not (ECOG 1 in the vast majority of
cases).
To further assess the safety of anti-PD-1 therapy in
this group of patients with significant medical co-
morbidities, we evaluated whether patients were hospi-
talized following anti-PD-1. Ten (37 %) patients were
hospitalized in the three months after the start of ther-
apy, including 5 for organ dysfunction, and 5 for other
reasons, primarily sepsis and syncope. Notably, at least 6
patients (22 %) were also hospitalized within 3 months
prior to therapy (albeit with incomplete records in some
cases); thus the attribution of anti-PD-1 for these find-
ings is unclear.
Efficacy
Thirteen patients (48 %) experienced ongoing treatment
benefit (partial response or stable disease) at the time of
data collection (Table 4). Eleven patients (41 %) had pri-
mary progressive disease, 11 (41 %) had stable disease as
best response, 4 (15 %) had partial responses, and one
(4 %) had a complete response. The patient with a
complete response received pembrolizumab for meta-
static melanoma and had baseline renal dysfunction at
baseline. Other partial responders included two pa-
tients with melanoma (one with baseline renal dysfunc-
tion and one with cirrhosis; Fig. 1a, b), a patient with
RCC, and a patient with NSCLC (both with baseline
renal dysfunction). These patients had ECOG PS ran-
ging from 0 to 3, and all had only a single organ dys-
function. Notably, the only patient categorized as
having an ECOG PS 3 was the complete responder with
melanoma. Among 3 patients on dialysis, none
responded to therapy, although none of these patients
experienced major toxicities either. Six patients (22 %)
experienced rapid progression and death within 60 days
of treatment initiation. Compared to the remainder of
the cohort, these patients did not appear to have par-
ticularly poor performance status (all with ECOG PS
listed as 1 by treating providers), or particularly severe
organ dysfunction (2 of 6 with multiple organs in-
volved, 1 of 6 on hemodialysis). The median PFS in this
cohort was 168 days, and the median OS was not
reached (Fig. 2).
Discussion
In this study, use of anti-PD-1 therapy in patients with
baseline organ dysfunction resulted in rates of irAEs
similar to previously reported clinical trials including pa-
tients without organ dysfunction. In this heavily pre-
treated population with multiple comorbid illnesses, we
demonstrate encouraging PFS and OS. Notably, exacer-
bation of baseline organ dysfunction was relatively un-
common, and was reversible with standard supportive
care (e.g. diuresis or intravenous fluid administration).
We speculate that the volume of fluid given with anti-
PD-1 therapy may have contributed to progression of
organ dysfunction, although we cannot rule out a drug-
specific effect. While these data are immature, they sug-
gest relative safety and efficacy in this patient population
without excess risk of irAEs that resulted in worsening
organ function. When taken in context with the favor-
able pharmacokinetics of pembrolizumab and nivolu-
mab, anti-PD-1 therapies are a viable treatment option
for this population.
Table 3 Organ dysfunction in individual patients
Baseline organ dysfunction Baseline measurements Worsening dysfunction (grade)
Renal and hepatic Creatinine 2.6, cirrhosis on imaging Edema (1)
Renal Creatinine 3.0 Acute kidney injury (2)
Renal Creatinine 2.2 Ascites (3)
Renal Creatinine 4.6 Acute kidney injury (1)
Renal and cardiac Creatinine 2.6, Ejection fraction 40 % Acute kidney injury (1), volume overload (3)
Cardiac Ejection fraction 30 % Decompensated heart failure (3)
Cardiac Ejection fraction 20 % Decompensated heart failure (3)
Liver and cardiac Ejection fraction 45 %, cirrhosis on imaging Volume overload and decompensated heart failure (3)
Table 4 Response to therapy
Response N (%)
Complete response 1 (4 %)
Partial response 4 (15 %)
Stable disease 11 (41 %)
Progressive disease 11 (41 %)
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Patients with baseline organ dysfunction represent a
population that may be more susceptible to adverse
events and is commonly excluded from clinical trials.
These patients may be unable to tolerate traditional
cytotoxic chemotherapy regimens due to organ dysfunc-
tion and poor performance status. Because of this, treat-
ment options and data to guide treatment decisions
may be limited. They have also been excluded from
clinical trials of immunotherapies, such as nivolumab
and pembrolizumab, with pharmacokinetic profiles
more amenable to this population. Our study showed
that anti-PD-1 agents may be a feasible alternative for
this challenging population.
This study adds to a growing body of literature for pa-
tients with common, relevant medical co-morbidities
that have been excluded from anti-PD-1 clinical trials.
Recent data from a retrospective multicenter study eval-
uated the tolerability of ipilimumab in patients with
baseline autoimmune diseases and similarly found that
these therapies may be reasonable options for patients
who are not traditionally included in standard clinical
trials [12]. Other groups have reported their experiences
with anti-PD-1 treatment in patients with prior organ
transplant and ongoing immunosuppression, as well as
patients with pre-existing hepatitis C and human
immunodeficiency virus [13–15]. While these agents
seemed largely safe and effective in patients with auto-
immunity and hepatitis C, several cases of rejection have
been observed in the organ transplant population. Inter-
estingly, and perhaps surprisingly, ipilimumab appears to
cause fewer rejection complications than does anti-PD-1
[16–18]. Further study in these clinically relevant popu-
lations is needed.
Our study has several other limitations. Patients re-
ceived treatment at four different centers over multiple
years, potentially resulting in variability in the quality of
data capture. Patient numbers overall were limited, lim-
iting the ability to draw definitive conclusions. Addition-
ally, the patients in this cohort had a median ECOG PS
of 1 with relatively few hospitalizations prior to treat-
ment. As such, they may represent a relatively healthier
group of patients with baseline organ dysfunction. Thus,
Fig. 1 PET-CT for a patient with metastatic melanoma and baseline cirrhosis of the liver (a) and near complete response four months after
initiating treatment (b)
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Fig. 2 Progression free (a) and overall survival (b) among the study population (median duration of follow-up 139 days)
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this study may not fully capture safety and efficacy of
anti-PD-1 in debilitated patients with more extensive co-
morbidities. Because the patients in this study had vari-
ous advanced malignancies, disease-specific conclusions
cannot be made. However, this is the largest study of
patients with solid tumors and significant baseline
organ dysfunction treated with anti-PD-1 therapy to
our knowledge.
Conclusion
In conclusion, anti-PD-1 agents are associated with tol-
erable irAEs and relatively infrequent progressive organ
dysfunction in patients with advanced malignancies and
baseline organ dysfunction. Objective responses and
prolonged PFS were observed. Prospective analyses
and longer term follow-up are required to validate
these findings.
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